image

REPORT SCOPE & OVERVIEW

The MicroRNA Market size was USD 1.58 Billion in 2022 and is expected to Reach USD 4.03 Billion by 2030 and grow at a CAGR of 12.44% over the forecast period of 2023-2030.

The microRNA (miRNA) market refers to the global market for microRNA-based products and services. MicroRNAs are tiny non-coding RNA molecules that play an important function in gene expression regulation. They are involved in various biological processes, including development, cell differentiation, and disease progression. The miRNA market encompasses a wide range of applications, including diagnostics, therapeutics, and research tools.

MicroRNA Market Revenue Analysis

MicroRNAs have gained significant attention as potential biomarkers for disease diagnosis and prognosis. They can be detected in various biological samples, such as blood, urine, and tissue, and their expression patterns can provide valuable information about diseases like cancer, cardiovascular disorders, and neurological conditions. Companies are developing miRNA-based diagnostic tests for early disease detection and personalized medicine. MicroRNA-based therapeutics aim to modulate gene expression and treat various diseases. By targeting specific microRNAs, researchers can potentially influence the expression of disease-related genes, leading to therapeutic benefits. This area is still in its early stages, with ongoing research and clinical trials focused on developing miRNA-based drugs for conditions like cancer, viral infections, and genetic disorders. MicroRNAs are essential tools for basic research and drug discovery.

Researchers use miRNA profiling techniques to study gene regulation, identify potential drug targets, and understand disease mechanisms. Several companies provide miRNA analysis kits, reagents, and services to facilitate miRNA research. The microRNA market has been experiencing steady growth due to the expanding understanding of microRNA biology, technological advancements in detection methods, and increasing demand for personalized medicine. However, it's important to note that the miRNA therapeutics segment is still in the early stages of development, and it may take time for miRNA-based drugs to gain regulatory approvals and enter the market. MiRNAs are becoming well known for their role in diagnosing and treating chronic illnesses such as cancer, liver disease, neurological disease, infectious disease, coronary heart disease, and metabolic disease. In the case of cancer, for example, overexpressed miRNAs are typically regarded as oncogenes. Some of these are expressed at extremely low levels in particular malignant cells and, in most cases, inhibit tumour formation. These miRNAs are known as tumour suppressor miRNAs. One of these tumour suppressor miRNAs is Let-7. As a result, one of the primary factors enhancing demand for such medications and fuelling the MicroRNA market growth is the therapeutic potential of miRNAs in many chronic disorders.

MARKET DYNAMICS

DRIVERS:

  • MicroRNAs have demonstrated potential as biomarkers for a variety of disorders. Because of their stability in physiological fluids and unique expression patterns, they are appealing candidates for diagnostic testing.

  • A growing number of clinical trials focusing on chronic diseases will drive market growth.

MiRNA's clinical and preclinical research applications are being expanded through ongoing investigations and clinical trials. An increasing body of evidence suggests that mRNAs have great usefulness as drug resistance modulators, biomarkers for pathogenic diseases, or medicines for medical intervention in practically all human health disorders. As a result, increasing the number of clinical trials for assessing the efficiency of miRNA in the treatment of various chronic illnesses is one of the significant factors boosting miRNA market expansion throughout the projection year.

RESTRAIN:

  • Intellectual property rights play a crucial role in the development and commercialization of miRNA-based products. The existing IP landscape around miRNAs, including patents and licensing agreements, can create barriers to entry for new players.

  • MiRNA safety and toxicity concerns may limit market growth in this market.

Several therapeutic uses have been linked to the advantages of miRNA. It is used to treat chronic diseases such as cancer, cardiovascular problems, renal disease, and so on. However, their safety and toxicity are still a topic of debate.

As a result, numerous companies have halted clinical trials for novel miRNA-based medicines. Mirna Therapeutics, Inc., a clinical-stage pharmaceutical company, announced that it will stop the present Phase 1 study of MRX34, its investigational therapy for a variety of cancers. Due to many immune-related serious adverse events (SAE) recorded in patients given MRX34 throughout the trial, the firm voluntarily terminated enrolment and dosage in the clinical research.

OPPORTUNITY:

  • miRNA-based therapeutics are still in the early stages of development, they hold significant promise for the treatment of various diseases. The ability of miRNAs to regulate multiple genes simultaneously opens up opportunities for targeted therapies and combination treatments.

  • Biomarker Discovery and Development is a big opportunity for this market.

MicroRNAs have shown promise as biomarkers for disease diagnosis, prognosis, and treatment response. The discovery and validation of new miRNA biomarkers can expand the range of diseases that can be detected and monitored. This presents opportunities for companies to develop innovative biomarker discovery platforms, diagnostic assays, and companion diagnostics for targeted therapies.

CHALLENGES:

  • The development and commercialization of miRNA-based products can be costly, including research and development, clinical trials, manufacturing, and regulatory compliance.

  • Market Fragmentation and Competition are the biggest challenges for this market.

The miRNA market is characterized by fragmentation, with multiple companies, academic institutions, and research organizations working on different aspects of miRNA research, diagnostics, and therapeutics. This fragmentation can lead to challenges in standardization, lack of consensus on methodologies, and difficulties in establishing unified guidelines or regulations. Competition among market players can also impact market dynamics and commercialization efforts.

IMPACT OF RUSSIAN UKRAINE WAR

The Russian invasion of Ukraine was described as a barbaric act. This is a pointer to how the war between Ukraine & Russia affects the pharmaceutical business in this region. Russia supplies 35-40% of its raw material to the world, which holds a huge share. After this war, many countries stopped taking raw materials from Russia. Russia had a loss of 4-5% profit which is come from raw materials. however, for many countries, there has been a lot of good scope in this field, which will be a deal of profit in the future, due to this war, the raw material, shipping price, and energy prices have also increased. An increase of 2-3% has been seen, as a result of which there is a boom in the equipment related to treatment in the microRNA sectors.

IMPACT OF ONGOING RECESSION

The fact that a lot of money is being invested in developing novel therapies for individuals with life-threatening illnesses is a major contributor to the growth in medical prices in Asian countries. Modern medical treatments and therapies for diseases such as cancer, transplants, and so on are also becoming more expensive as they advance. Nowadays, the majority of the equipment used in top-tier hospitals is imported from other countries, which has resulted in an increase in medical prices.

Increased utilisation and nursing demands in ambulatory, hospital-based outpatient departments, home care, skilled nursing institutions, and hospice settings might result in an 8% to 10% yearly rise in registered nurse demand between 2021 and 2025. At the same time, higher-than-normal attrition (8% per year in 2021 and 2022 before returning to an estimated 2% to 5% in 2023) and retirements will outnumber new licensures, reducing the total number of registered nurses working in direct patient care just as the number of required roles grows. After 2022, the attrition rate should return to normal. This ongoing recession does not see a major impact on microRNA markets.

KEY MARKET SEGMENTS

By Products & Services

  • Profiling

  • Quantification

  • Localization

By Application

  • Neurological Disease

  • Cancer

By End Users

  • Academic & Government Research Institutes

  • Biotechnology & Pharmaceutical Companies

  • Other

MicroRNA Market Segmentation Analysis

REGIONAL COVERAGE:

North America

  • US

  • Canada

  • Mexico

Europe

  • Eastern Europe

    • Poland

    • Romania

    • Hungary

    • Turkey

    • Rest of Eastern Europe

  • Western Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Netherlands

    • Switzerland

    • Austria

    • Rest of Western Europe

Asia Pacific

  • China

  • India

  • Japan

  • South Korea

  • Vietnam

  • Singapore

  • Australia

  • Rest of Asia Pacific

Middle East & Africa

  • Middle East

    • UAE

    • Egypt

    • Saudi Arabia

    • Qatar

    • Rest of Middle East

  • Africa

    • Nigeria

    • South Africa

    • Rest of Africa

Latin America

  • Brazil

  • Argentina

  • Colombia

  • Rest of Latin America

REGIONAL ANALYSIS

North America: Due to increased expenditures in research and development activities in the area, the region will continue its dominance over the worldwide market over the projection period. Furthermore, the existence of key competitors with the ability to engage in R&D activities adds to the growth of the market in North America. Along with major advances, the region's availability of easy and speedy procedures for obtaining approvals for microRNA biomarkers supplements the market's expansion. Massive contributors to the North American market include Synlogic, Thermo Fisher Scientific, ProMega Corporation, and SeqMatic.

Asia Pacific: The region's quickly growing population, rising frequency of cardiovascular disorders, higher need for microRNA-based therapeutics, and greater emphasis on research & development activities are just a few of the reasons driving market expansion. For example, MiRXES, located in Singapore, announced in 2022 its cooperation with the National University Heart Centres and the National Heart Centre, Singapore, to control pulmonary hypertension. The partnership has resulted in the commencement of Southeast Asia's first multi-centre research using early detection microRNA biomarkers. The centre’s goal is to employ microRNA biomarkers to diagnose pulmonary hypertension early.

Key players 

Some major key players in MicroRNA Market are QIAGEN, Merck KGaA, Synlogic, Thermo Fisher Scientific Inc., Horizon Discovery Ltd., GeneCopoeia, Inc, New England Biolabs, NanoString, Quantabio, BioGenex and other players.

Synlogic-Company Financial Analysis

RECENT DEVELOPMENT

Sistemic Ltd: Sistemic Ltd announced the extension of their patent covering the use of microRNAs as predictive analytes for cellular function. The patent covers the investigation of microRNA expression in mesenchymal stem cells collected from multiple donors in order to find miRNAs that will be associated with cellular activities in order to help donor screening and the development of MSC-based cell treatments.

DiamiR: DiamiR got U.S. Patent clearance for miRNA-based systems for identifying and monitoring brain aging. The patent addresses the application of quantitative techniques for analyzing detectable miRNA in blood plasma and the brain as brain ageing indicators.

MicroRNA Market Report Scope:
Report Attributes Details
Market Size in 2022  US$ 1.58 Bn
Market Size by 2030  US$ 4.03 Bn
CAGR   CAGR of 12.44% From 2023 to 2030
Base Year  2022
Forecast Period  2023-2030
Historical Data  2020-2021
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Products & Services (Profiling, Quantification, and Localization)
• By Application (Neurological Disease, Cancer)
• By End User (Academic & Government Research Institutes, Biotechnology & Pharmaceutical Companies, Other)
Regional Analysis/Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]). Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America)
Company Profiles QIAGEN, Merck KGaA, Synlogic, Thermo Fisher Scientific Inc., Horizon Discovery Ltd., GeneCopoeia, Inc, New England Biolabs, NanoString, Quantabio, BioGenex
Key Drivers • MicroRNAs have demonstrated potential as biomarkers for a variety of disorders. Because of their stability in physiological fluids and unique expression patterns, they are appealing candidates for diagnostic testing.
• A growing number of clinical trials focusing on chronic diseases will drive market growth.
Market Restraints • Intellectual property rights play a crucial role in the development and commercialization of miRNA-based products. The existing IP landscape around miRNAs, including patents and licensing agreements, can create barriers to entry for new players.
• MiRNA safety and toxicity concerns may limit market growth in this market.

 

Frequently Asked Questions

Ans:  The MicroRNA Market is estimated to develop at a 12.64% CAGR.

Ans: The MicroRNA Market was valued at USD 1.58 billion in 2022 and is predicted to grow to USD 4.03 billion by 2030.

Ans: By Products & Services, The profiling, Quantification, and Localization segment will lead the market.

Ans: The increased need for improved diagnostic outcomes fuels and real-time polymerase chain reactions are expected to dominate the microRNA industry.

Ans: In 2022, microRNA-related profiling, localisation, and quantification services held a 24.84% share of the microRNA market. This is due to a rise in functional studies to examine the role of various miRNAs in various illnesses, as well as the increased usage of modern technologies like as NGS for reliable detection and quantification of miRNAs.

Table of Contents

1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions

2. Research Methodology

3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges

4. Impact Analysis
4.1 Impact of Russia-Ukraine War
4.2 Impact of Ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
4.3 Supply Demand Gap Analysis

5. Value Chain Analysis

6. Porter’s 5 forces model

7. PEST Analysis

8. MicroRNA Market Segmentation, By Products & Services
8.1 Profiling
8.2 Quantification
8.3 Localization

9. MicroRNA Market Segmentation, By Application
9.1 Neurological Disease
9.2 Cancer

10. MicroRNA Market Segmentation, By End User
10.1 Academic & Government Research Institutes
10.2 Biotechnology & Pharmaceutical Companies
10.3 Other

11. Regional Analysis
11.1 Introduction
11.2 North America
11.2.1 North America MicroRNA Market by Country
11.2.2 North America MicroRNA Market by Products & Services
11.2.3 North America MicroRNA Market by Application
11.2.4 North America MicroRNA Market by End User
11.2.5 USA
11.2.5.1 USA MicroRNA Market by Products & Services
11.2.5.2 USA MicroRNA Market by Application
11.2.5.3 USA MicroRNA Market by End User
11.2.6 Canada
11.2.6.1 Canada MicroRNA Market by Products & Services
11.2.6.2 Canada MicroRNA Market by Application
11.2.6.3 Canada MicroRNA Market by End User
11.2.7 Mexico
11.2.7.1 Mexico MicroRNA Market by Products & Services
11.2.7.2 Mexico MicroRNA Market by Application
11.2.7.3 Mexico MicroRNA Market by End User
11.3 Europe
11.3.1 Eastern Europe
11.3.1.1 Eastern Europe MicroRNA Market by Country
11.3.1.2 Eastern Europe MicroRNA Market by Products & Services
11.3.1.3 Eastern Europe MicroRNA Market by Application
11.3.1.4 Eastern Europe MicroRNA Market by End User
11.3.1.5 Poland
11.3.1.5.1 Poland MicroRNA Market by Products & Services
11.3.1.5.2 Poland MicroRNA Market by Application
11.3.1.5.3 Poland MicroRNA Market by End User
11.3.1.6 Romania
11.3.1.6.1 Romania MicroRNA Market by Products & Services
11.3.1.6.2 Romania MicroRNA Market by Application
11.3.1.6.4 Romania MicroRNA Market by End User
11.3.1.7 Turkey
11.3.1.7.1 Turkey MicroRNA Market by Products & Services
11.3.1.7.2 Turkey MicroRNA Market by Application
11.3.1.7.3 Turkey MicroRNA Market by End User
11.3.1.8 Rest of Eastern Europe
11.3.1.8.1 Rest of Eastern Europe MicroRNA Market by Products & Services
11.3.1.8.2 Rest of Eastern Europe MicroRNA Market by Application
11.3.1.8.3 Rest of Eastern Europe MicroRNA Market by End User
11.3.2 Western Europe
11.3.2.1 Western Europe MicroRNA Market by Country
11.3.2.2 Western Europe MicroRNA Market by Products & Services
11.3.2.3 Western Europe MicroRNA Market by Application
11.3.2.4 Western Europe MicroRNA Market by End User
11.3.2.5 Germany
11.3.2.5.1 Germany MicroRNA Market by Products & Services
11.3.2.5.2 Germany MicroRNA Market by Application
11.3.2.5.3 Germany MicroRNA Market by End User
11.3.2.6 France
11.3.2.6.1 France MicroRNA Market by Products & Services
11.3.2.6.2 France MicroRNA Market by Application
11.3.2.6.3 France MicroRNA Market by End User
11.3.2.7 UK
11.3.2.7.1 UK MicroRNA Market by Products & Services
11.3.2.7.2 UK MicroRNA Market by Application
11.3.2.7.3 UK MicroRNA Market by End User
11.3.2.8 Italy
11.3.2.8.1 Italy MicroRNA Market by Products & Services
11.3.2.8.2 Italy MicroRNA Market by Application
11.3.2.8.3 Italy MicroRNA Market by End User
11.3.2.9 Spain
11.3.2.9.1 Spain MicroRNA Market by Products & Services
11.3.2.9.2 Spain MicroRNA Market by Application
11.3.2.9.3 Spain MicroRNA Market by End User
11.3.2.10 Netherlands
11.3.2.10.1 Netherlands MicroRNA Market by Products & Services
11.3.2.10.2 Netherlands MicroRNA Market by Application
11.3.2.10.3 Netherlands MicroRNA Market by End User
11.3.2.11 Switzerland
11.3.2.11.1 Switzerland MicroRNA Market by Products & Services
11.3.2.11.2 Switzerland MicroRNA Market by Application
11.3.2.11.3 Switzerland MicroRNA Market by End User
11.3.2.1.12 Austria
11.3.2.12.1 Austria MicroRNA Market by Products & Services
11.3.2.12.2 Austria MicroRNA Market by Application
11.3.2.12.3 Austria MicroRNA Market by End User
11.3.2.13 Rest of Western Europe
11.3.2.13.1 Rest of Western Europe MicroRNA Market by Products & Services
11.3.2.13.2 Rest of Western Europe MicroRNA Market by Application
11.3.2.13.3 Rest of Western Europe MicroRNA Market by End User
11.4 Asia-Pacific
11.4.1 Asia-Pacific MicroRNA Market by Country
11.4.2 Asia-Pacific MicroRNA Market by Products & Services
11.4.3 Asia-Pacific MicroRNA Market by Application
11.4.4 Asia-Pacific MicroRNA Market by End User
11.4.5 China
11.4.5.1 China MicroRNA Market by Products & Services
11.4.5.2 China MicroRNA Market by End User
11.4.5.3 China MicroRNA Market by Application
11.4.6 India
11.4.6.1 India MicroRNA Market by Products & Services
11.4.6.2 India MicroRNA Market by Application
11.4.6.3 India MicroRNA Market by End User
11.4.7 japan
11.4.7.1 Japan MicroRNA Market by Products & Services
11.4.7.2 Japan MicroRNA Market by Application
11.4.7.3 Japan MicroRNA Market by End User
11.4.8 South Korea
11.4.8.1 South Korea MicroRNA Market by Products & Services
11.4.8.2 South Korea MicroRNA Market by Application
11.4.8.3 South Korea MicroRNA Market by End User
11.4.9 Vietnam
11.4.9.1 Vietnam MicroRNA Market by Products & Services
11.4.9.2 Vietnam MicroRNA Market by Application
11.4.9.3 Vietnam MicroRNA Market by End User
11.4.10 Singapore
11.4.10.1 Singapore MicroRNA Market by Products & Services
11.4.10.2 Singapore MicroRNA Market by Application
11.4.10.3 Singapore MicroRNA Market by End User
11.4.11 Australia
11.4.11.1 Australia MicroRNA Market by Products & Services
11.4.11.2 Australia MicroRNA Market by Application
11.4.11.3 Australia MicroRNA Market by End User
11.4.12 Rest of Asia-Pacific
11.4.12.1 Rest of Asia-Pacific MicroRNA Market by Products & Services
11.4.12.2 Rest of Asia-Pacific MicroRNA Market by Application
11.4.12.3 Rest of Asia-Pacific MicroRNA Market by End User
11.5 Middle East & Africa
11.5.1 Middle East
11.5.1.1 Middle East MicroRNA Market by Country
11.5.1.2 Middle East MicroRNA Market by Products & Services
11.5.1.3 Middle East MicroRNA Market by Application
11.5.1.4 Middle East MicroRNA Market by End User
11.5.1.5 UAE
11.5.1.5.1 UAE MicroRNA Market by Products & Services
11.5.1.5.2 UAE MicroRNA Market by Application
11.5.1.5.3 UAE MicroRNA Market by End User
11.5.1.6 Egypt
11.5.1.6.1 Egypt MicroRNA Market by Products & Services
11.5.1.6.2 Egypt MicroRNA Market by Application
11.5.1.6.3 Egypt MicroRNA Market by End User
11.5.1.7 Saudi Arabia
11.5.1.7.1 Saudi Arabia MicroRNA Market by Products & Services
11.5.1.7.2 Saudi Arabia MicroRNA Market by Application
11.5.1.7.3 Saudi Arabia MicroRNA Market by End User
11.5.1.8 Qatar
11.5.1.8.1 Qatar MicroRNA Market by Products & Services
11.5.1.8.2 Qatar MicroRNA Market by Application
11.5.1.8.3 Qatar MicroRNA Market by End User
11.5.1.9 Rest of Middle East
11.5.1.9.1 Rest of Middle East MicroRNA Market by Products & Services
11.5.1.9.2 Rest of Middle East MicroRNA Market by Application
11.5.1.9.3 Rest of Middle East MicroRNA Market by End User
11.5.2 Africa
11.5.2.1 Africa MicroRNA Market by Country
11.5.2.2 Africa MicroRNA Market by Products & Services
11.5.2.3 Africa MicroRNA Market by Application
11.5.2.4 Africa MicroRNA Market by End User
11.5.2.5 Nigeria
11.5.2.5.1 Nigeria MicroRNA Market by Products & Services
11.5.2.5.2 Nigeria MicroRNA Market by Application
11.5.2.5.3 Nigeria MicroRNA Market by End User
11.5.2.6 South Africa
11.5.2.6.1 South Africa MicroRNA Market by Products & Services
11.5.2.6.2 South Africa MicroRNA Market by Application
11.5.2.6.3 South Africa MicroRNA Market by End User
11.5.2.7 Rest of Africa
11.5.2.7.1 Rest of Africa MicroRNA Market by Products & Services
11.5.2.7.2 Rest of Africa MicroRNA Market by Application
11.5.2.7.3 Rest of Africa MicroRNA Market by End User
11.6 Latin America
11.6.1 Latin America MicroRNA Market by Country
11.6.2 Latin America MicroRNA Market by Products & Services
11.6.3 Latin America MicroRNA Market by Application
11.6.4 Latin America MicroRNA Market by End User
11.6.5 Brazil
11.6.5.1 Brazil America MicroRNA Market by Products & Services
11.6.5.2 Brazil America MicroRNA Market by Application
11.6.5.3 Brazil America MicroRNA Market by End User
11.6.6 Argentina
11.6.6.1 Argentina America MicroRNA Market by Products & Services
11.6.6.2 Argentina America MicroRNA Market by Application
11.6.6.3 Argentina America MicroRNA Market by End User
11.6.7 Colombia
11.6.7.1 Colombia America MicroRNA Market by Products & Services
11.6.7.2 Colombia America MicroRNA Market by Application
11.6.7.3 Colombia America MicroRNA Market by End User
11.6.8 Rest of Latin America
11.6.8.1 Rest of Latin America MicroRNA Market by Products & Services
11.6.8.2 Rest of Latin America MicroRNA Market by Application
11.6.8.3 Rest of Latin America MicroRNA Market by End User

12 Company profile
12.1 QIAGEN
12.1.1 Company Overview
12.1.2 Financials
12.1.3 Product/Services Offered
12.1.4 SWOT Analysis
12.1.5 The SNS View
12.2 Merck KGaA
12.2.1 Company Overview
12.2.2 Financials
12.2.3 Product/Services Offered
12.2.4 SWOT Analysis
12.2.5 The SNS View
12.3 Synlogic
12.3.1 Company Overview
12.3.2 Financials
12.3.3 Product/Services Offered
12.3.4 SWOT Analysis
12.3.5 The SNS View
12.4 Thermo Fisher Scientific Inc
12.4.1 Company Overview
12.4.2 Financials
12.4.3 Product/Services Offered
12.4.4 SWOT Analysis
12.4.5 The SNS View
12.5 Horizon Discovery Ltd
12.5.1 Company Overview
12.5.2 Financials
12.5.3 Product/Services Offered
12.5.4 SWOT Analysis
12.5.5 The SNS View
12.6 GeneCopoeia, Inc
12.6.1 Company Overview
12.6.2 Financials
12.6.3 Product/Services Offered
12.6.4 SWOT Analysis
12.6.5 The SNS View
12.7 New England Biolabs
12.7.1 Company Overview
12.7.2 Financials
12.7.3 Product/Services Offered
12.7.4 SWOT Analysis
12.7.5 The SNS View
12.8 NanoString
12.8.1 Company Overview
12.8.2 Financials
12.8.3 Product/Services Offered
12.8.4 SWOT Analysis
12.8.5 The SNS View
12.9 Quantabio
12.9.1 Company Overview
12.9.2 Financials
12.9.3 Product/Services Offered
12.9.4 SWOT Analysis
12.9.5 The SNS View
12.10 BioGenex
12.10.1 Company Overview
12.10.2 Financials
12.10.3 Product/Services Offered
12.10.4 SWOT Analysis
12.10.5 The SNS View

13. Competitive Landscape
13.1 Competitive Benchmarking
13.2 Market Share Analysis
13.3 Recent Developments
13.3.1 Industry News
13.3.2 Company News
13.3.3 Mergers & Acquisitions

13. USE Cases and Best Practices

14. Conclusion

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

 

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Primary Research

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Data Bank Validation

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.

Start a Conversation

Hi! Click one of our member below to chat on Phone